Edition:
United Kingdom

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

5.97EUR
22 Mar 2019
Change (% chg)

€-0.13 (-2.13%)
Prev Close
€6.11
Open
€6.06
Day's High
€6.06
Day's Low
€5.88
Volume
83,386
Avg. Vol
117,933
52-wk High
€9.38
52-wk Low
€4.36

Chart for

About

Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients.... (more)

Overall

Beta: 0.53
Market Cap(Mil.): €275.62
Shares Outstanding(Mil.): 29.17
Dividend: --
Yield (%): --

Financials

  NCOX.PA Industry Sector
P/E (TTM): -- 29.30 32.54
EPS (TTM): -0.24 -- --
ROI: -5.13 14.23 13.82
ROE: -6.82 15.46 15.25

Nicox teams up with Chinese firm to develop and sell glaucoma drug

PARIS French ophthalmology company Nicox and Chinese firm Ocumension Therapeutics said on Monday they had signed an exclusive licence agreement to develop and sell a yet-to-be approved Nicox drug to treat glaucoma in China.

17 Dec 2018

Nicox teams up with Chinese firm to develop and sell glaucoma drug

PARIS French ophthalmology company Nicox and Chinese firm Ocumension Therapeutics said on Monday they had signed an exclusive license agreement to develop and sell a yet-to-be approved Nicox drug to treat glaucoma in China.

17 Dec 2018

Nicox teams up with Chinese firm to develop and sell glaucoma drug

PARIS, Dec 17 French ophthalmology company Nicox and Chinese firm Ocumension Therapeutics said on Monday they had signed an exclusive licence agreement to develop and sell a yet-to-be approved Nicox drug to treat glaucoma in China.

17 Dec 2018

Healthcare group Nicox postpones NASDAQ listing due to market volatility

PARIS, Oct 30 French healthcare and ophthalmology company Nicox said it had decided to postpone plans to list shares on the U.S. NASDAQ stock market, in the latest example of a company dropping stock market flotation plans due to market volatility.

30 Oct 2018

Earnings vs. Estimates